- Home
- KPRX vs MYNZ Comparison
KPRX vs MYNZ Comparison
Compare KPRX & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- MYNZ
- Stock Information
- Founded
- KPRX 1998
- MYNZ 2021
- Country
- KPRX United States
- MYNZ Germany
- Employees
- KPRX N/A
- MYNZ N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- KPRX Health Care
- MYNZ Health Care
- Exchange
- KPRX Nasdaq
- MYNZ Nasdaq
- Market Cap
- KPRX 9.2M
- MYNZ 7.9M
- IPO Year
- KPRX N/A
- MYNZ 2021
- Fundamental
- Price
- KPRX $2.15
- MYNZ $1.27
- Analyst Decision
- KPRX Strong Buy
- MYNZ Buy
- Analyst Count
- KPRX 1
- MYNZ 2
- Target Price
- KPRX $10.00
- MYNZ $14.00
- AVG Volume (30 Days)
- KPRX 53.1K
- MYNZ 795.6K
- Earning Date
- KPRX 11-07-2025
- MYNZ 12-29-2025
- Dividend Yield
- KPRX N/A
- MYNZ N/A
- EPS Growth
- KPRX N/A
- MYNZ N/A
- EPS
- KPRX N/A
- MYNZ N/A
- Revenue
- KPRX N/A
- MYNZ $659,935.00
- Revenue This Year
- KPRX N/A
- MYNZ N/A
- Revenue Next Year
- KPRX N/A
- MYNZ $5.03
- P/E Ratio
- KPRX N/A
- MYNZ N/A
- Revenue Growth
- KPRX N/A
- MYNZ N/A
- 52 Week Low
- KPRX $2.05
- MYNZ $1.21
- 52 Week High
- KPRX $4.18
- MYNZ $10.56
- Technical
- Relative Strength Index (RSI)
- KPRX 33.03
- MYNZ 36.88
- Support Level
- KPRX $2.26
- MYNZ $1.21
- Resistance Level
- KPRX $2.39
- MYNZ $2.09
- Average True Range (ATR)
- KPRX 0.14
- MYNZ 0.17
- MACD
- KPRX -0.02
- MYNZ -0.01
- Stochastic Oscillator
- KPRX 16.03
- MYNZ 5.51
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.